At a Glance
- Investors in Soleno Therapeutics, Inc. face a July 15, 2024 deadline to apply for lead plaintiff status in a securities class action lawsuit.
- The lawsuit alleges Soleno made misleading statements regarding its lead product candidate, DCCR, for Prader-Willi syndrome.
- Allegations include overstating DCCR's efficacy and safety, and issues with the Phase 3 DESTINY PWS trial design.
Soleno Therapeutics, Inc. (NASDAQ: SLNO) is facing a securities class action lawsuit, with an important deadline approaching for investors. Purchasers of Soleno Therapeutics securities between October 21, 2021, and November 1, 2023, must move the Court for lead plaintiff status by July 15, 2024. The lawsuit, filed by Rosen Law Firm, alleges that the company made false and misleading statements during this period.
Allegations of Misleading Statements and Trial Issues
The class action lawsuit claims that Soleno Therapeutics overstated the efficacy and safety of DCCR (dextromethorphan-hydroxypropyl-beta-cyclodextrin), its primary product candidate for Prader-Willi syndrome (PWS). Specifically, the complaint suggests the company did not adequately account for the unique design of its Phase 3 DESTINY PWS trial.
This alleged oversight reportedly led to unreliable trial results, which would likely pose significant challenges for DCCR's approval by the U.S. Food and Drug Administration (FDA). The lawsuit contends that Soleno's public statements were materially false and misleading throughout the specified Class Period.
These concerns became public on November 2, 2023, when Soleno announced its third-quarter financial results and a business update. The company disclosed that the FDA advised a new bridging study was required due to a formulation change in DCCR from earlier trials. The FDA also indicated the DESTINY PWS trial alone was insufficient to support a New Drug Application (NDA), necessitating a new Phase 3 clinical trial.
Following this announcement, Soleno’s stock price experienced a significant decline. Shares fell $22.28, or 69.2%, closing at $9.92 per share on November 2, 2023, causing substantial investor losses.
"Investors who suffered losses are encouraged to secure legal counsel before the upcoming deadline to protect their interests."
— Laurence Rosen, Founder, Rosen Law Firm
Understanding the Lead Plaintiff Role and Investor Options
The securities class action lawsuit seeks to recover damages on behalf of all affected Soleno Therapeutics investors. The deadline of July 15, 2024, is crucial for investors wishing to serve as a lead plaintiff in the action.
A lead plaintiff acts as a representative party, guiding the litigation on behalf of other class members. While serving as lead plaintiff is not mandatory for potential recovery, it offers a direct role in the legal proceedings.
Investors who purchased Soleno Therapeutics securities during the Class Period may be entitled to compensation without incurring out-of-pocket fees or costs through a contingency fee arrangement. The lawsuit has already been filed, and investors have the option to retain their own counsel or remain an absent class member.
The outcome of the class action will depend on the legal process and judicial decisions, with the goal of recovering damages for investors who allegedly suffered losses due to the company's actions. No class has yet been certified, meaning investors are not represented by counsel unless they choose to retain one individually.